Bristol-Myers Squibb
BMY
2,470 hedge funds and large institutions have $116B invested in Bristol-Myers Squibb in 2022 Q3 according to their latest regulatory filings, with 98 funds opening new positions, 992 increasing their positions, 1,017 reducing their positions, and 134 closing their positions.
26% more call options, than puts
Call options by funds: $1.98B | Put options by funds: $1.58B
0.31% less ownership
Funds ownership: 77.33% → 77.02% (-0.31%)
2% less repeat investments, than reductions
Existing positions increased: 992 | Existing positions reduced: 1,017
3% less funds holding
Funds holding: 2,538 → 2,470 (-68)
8% less capital invested
Capital invested by funds: $126B → $116B (-$9.75B)
14% less funds holding in top 10
Funds holding in top 10: 132 → 113 (-19)
27% less first-time investments, than exits
New positions opened: 98 | Existing positions closed: 134
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital International Investors
Los Angeles,
California
|
+$1.04B |
| 2 |
Janus Henderson Group
London,
United Kingdom
|
+$583M |
| 3 |
Boston Partners
Boston,
Massachusetts
|
+$374M |
| 4 |
Norges Bank
Oslo,
Norway
|
+$265M |
| 5 |
BlackRock
New York
|
+$244M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$617M |
| 2 |
Morgan Stanley
New York
|
-$479M |
| 3 |
BNP Paribas Financial Markets
Paris,
France
|
-$287M |
| 4 |
Franklin Resources
San Mateo,
California
|
-$245M |
| 5 |
Canada Pension Plan Investment Board
Toronto Ontario,
Ontario, Canada
|
-$201M |
BMY Hedge Fund Activity: Q3 2022 in Review
2,470 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in Bristol-Myers Squibb (BMY) for Q3 2022, worth a combined $116B — down 7.7% from $126B a quarter earlier.
Sellers outnumbered buyers: 134 funds closed out of BMY and 98 opened new positions — a net loss of 36 holders — while 1,017 trimmed existing stakes and 992 added.
The largest buyer was Capital International Investors, adding an estimated $1.04B. The largest seller was T. Rowe Price Associates, cutting an estimated $617M.
- 2,470 institutional investors held Bristol-Myers Squibb (BMY) as of Q3 2022, down from 2,538 in Q2 2022.
- Funds reported $116B of Bristol-Myers Squibb stock for Q3 2022, down 7.7% quarter-over-quarter.
- 98 funds opened new Bristol-Myers Squibb positions in Q3 2022 and 134 closed out, a net change of -36 holders.
- The largest Bristol-Myers Squibb buyer in Q3 2022 was Capital International Investors, an estimated $1.04B added.
- The largest Bristol-Myers Squibb seller in Q3 2022 was T. Rowe Price Associates, an estimated $617M sold.
Based on aggregated 13F filings for Q3 2022.